In this information-packed webinar, neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation (TPS) in patients with Alzheimer’s Dementia as well as practical experience with handling and clinical effects.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey.
Transcranial Pulse Stimulation (TPS) celebrates its debut in Ukraine: The first NEUROLITH® system was installed in the western Ukrainian city and cultural centre of Lviv (approx. 750,000 inhabitants) on 12 January 2022. Now, Alzheimer's patients can receive treatment at »BRAINSPOT LVIV«, a clinic for neuromodulation (Director: Tomas Dzeminskyy, Chief Medical Officer: Andrii Hul). The first therapy sessions have already taken place.
A study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in January 2022 investigates the long-term effects of Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system on human brain and behaviour.1 The randomised, sham-controlled and double-blinded study provides sham-controlled evidence for such effects for the first time.
Another study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in February 2022 now presented a detailed sub-analysis of possible anti-depressive effects of Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system based on neuropsychological and functional...
In December 2019, the first study1 on Transcranial Pulse Stimulation (TPS) with STORZ MEDICAL’s NEUROLITH® system was published in the prestigious journal Advanced Science. In the study, Beisteiner et al. evaluate the TPS method and present treatment results. The presented data shows that it is possible to improve brain performance with TPS and that there is a long-term effect.
